Regeneron Pharmaceuticals, Inc.
REGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $58,262 | $55,178 | $67,672 | $76,860 |
| - Cash | $2,506 | $1,996 | $3,090 | $2,488 |
| + Debt | $2,706 | $2,705 | $2,705 | $2,704 |
| Enterprise Value | $58,461 | $55,887 | $67,287 | $77,077 |
| Revenue | $3,754 | $3,676 | $3,029 | $3,789 |
| % Growth | 2.1% | 21.4% | -20.1% | – |
| Gross Profit | $3,233 | $3,145 | $2,564 | $3,224 |
| % Margin | 86.1% | 85.6% | 84.7% | 85.1% |
| EBITDA | $1,919 | $1,657 | $1,041 | $1,095 |
| % Margin | 51.1% | 45.1% | 34.4% | 28.9% |
| Net Income | $1,460 | $1,392 | $809 | $918 |
| % Margin | 38.9% | 37.9% | 26.7% | 24.2% |
| EPS Diluted | 13.62 | 12.81 | 7.27 | 8.06 |
| % Growth | 6.3% | 76.2% | -9.8% | – |
| Operating Cash Flow | $1,619 | $1,144 | $1,045 | $1,263 |
| Capital Expenditures | -$201 | -$177 | -$272 | -$267 |
| Free Cash Flow | $1,417 | $968 | $774 | $996 |